Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist ...
Sep 16, 2025 · Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity.
An in-depth analysis for researchers and drug development professionals on the comparative efficacy, mechanisms of action, and clinical trial designs of the novel oral GLP-1 receptor agonist, orforglipron, …
Efficacy and safety of oral orforglipron in patients with ...
Aug 5, 2023 · Orforglipron, an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist, is in development for type 2 diabetes and obesity. We assessed the efficacy and safety of orforglipron …
Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic ...
Jun 11, 2025 · Small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent an innovative advancement in oral therapeutics, addressing key limitations associated with injectable …
Data on 3 New GLP-1 Drugs for Weight Loss That May Be ...
Jan 30, 2026 · The pill is orforglipron, a different GLP-1 receptor agonist. “I would be surprised if not all of them are approved,” said Robert Kushner, MD, a Northwestern University nutrition and weight …
Lilly's oral GLP-1, orforglipron, demonstrated statistically ...
Apr 17, 2025 · Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses. The investigational once-daily oral pill …
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes ...
Jun 6, 2024 · In ongoing trials investigators are interrogating the efficacy of these agents for new indications, including metabolic liver disease, peripheral artery disease, Parkinson disease, and …